R.A. joined AveXis in 2017, a biotech firm committed to moving gene therapies into the clinical setting for patients and families affected by rare and orphan neurological genetic diseases. As SVP and Head of Corporate Strategy, he also has responsibility for business development, alliance, and project management.
R.A. was previously at PTC Therapeutics, serving as VP of Commercial Development and before that VP of Corporate Development. He worked cross-functionally in corporate strategy, portfolio planning, commercial development, and finance. PTC is a biopharmaceutical company focused on the discovery and development of small-molecule drugs that target the post-transcriptional control processes. He had an earlier tenure at the firm as Associate Director of Strategic Planning & Finance.
Before joining PTC, R.A. was Senior Director, Strategic Planning & Finance at Reata Pharmaceuticals, where he led long-range planning, valuation analysis, market access, pricing, and financial analytics. R.A. has held various positions in drug development, finance, and commercial operations at other leading biopharmaceutical companies including AstraZeneca and Johnson & Johnson.
Education, Personal, and Fellowship
RA holds an MBA and an MSF from Texas A&M University at Commerce, College of Business and Technology and a BSBA from the University of North Carolina at Charlotte, Belk College of Business where he was a member of the NCAA ranked men?s soccer team.
RA served his fellowship at PTC under the mentorship of company president Claudia Hirawat; he is a member of Class 19.